Cas9 Stable Cell Line - 5637

The Cas9-Stable Cell Line—5637 is a genetically engineered cell line derived from the human bladder cancer cell line 5637. This cell line has been modified to stably express CRISPR-associated protein 9 (Cas9), a key component of the CRISPR-Cas9 genome editing system. The parental 5637 cells were originally derived from a 68-year-old female patient with bladder cancer; these cells exhibit an epithelial morphology and are widely utilized in cancer research due to their significant relevance in the study of urothelial carcinoma. The stable integration of the Cas9 nuclease into these cells ensures the continuous and long-term expression of the Cas9 protein, thereby eliminating the need for repetitive transfection procedures and significantly enhancing experimental reproducibility. Key features of the Cas9-Stable Cell Line—5637 include: exceptionally high gene editing efficiency, robust growth characteristics under standard culture conditions, and high compatibility with various sgRNA delivery methods; these attributes make it a powerful tool for conducting targeted gene modification studies.

As a versatile platform, the Cas9-Stable Cell Line—5637 finds broad application across various fields of biomedical research. In functional genomics, this cell line can be utilized to conduct high-throughput loss-of-function screens, thereby identifying genes critical to the initiation, progression, drug resistance, or metastasis of bladder cancer. By employing this cell line, researchers can rapidly generate knockout models for tumor suppressor genes or oncogenes, enabling a deeper mechanistic dissection of key signaling pathways—such as PI3K/AKT or TP53. In the realm of drug discovery and development, this cell line facilitates drug target validation by enabling the creation of isogenic cell pairs (i.e., matched sets of wild-type and gene-edited cells), allowing researchers to assess the efficacy and specificity of candidate compounds. Furthermore, it supports investigations into "synthetic lethality" effects—studies aimed at uncovering potential vulnerabilities within tumor cells to provide a theoretical basis for the development of precision oncology strategies. Beyond cancer research, this cell line can also aid in modeling various genetic disorders—by introducing patient-specific gene mutations—and can be used to evaluate the efficacy of corresponding gene repair or therapeutic intervention strategies.